Cancer Cell Diagnostics Launches New Blood Test for Cancer Profiling
The test uses intact circulating tumor cells instead of cell-free DNA fragments to analyze more than 500 genes and identify tumor markers.
Read MorePosted by CLP Edit Staff | Jul 23, 2026 | Cancer, Molecular Diagnostics |
The test uses intact circulating tumor cells instead of cell-free DNA fragments to analyze more than 500 genes and identify tumor markers.
Read MorePosted by CLP Edit Staff | Jul 21, 2026 | Company News, Molecular Diagnostics |
Myriad Genetics has launched the FirstGene Multiple Prenatal Screen, a test that combines four prenatal genetic screens from a single blood draw as early as eight weeks gestation, according to the company.
Read MorePosted by CLP Edit Staff | Jul 21, 2026 | Prostate |
A new study in The Journal of Nuclear Medicine reports that a noninvasive DNA blood test can help select advanced prostate cancer patients most likely to benefit from 223Ra radiopharmaceutical therapy and monitor treatment response.
Read MorePosted by CLP Edit Staff | Jul 21, 2026 | Accreditation, Compliance |
The request for information addresses advancements in technology, including artificial intelligence and cybersecurity, to inform potential changes to 1992 rules.
Read MorePosted by CLP Edit Staff | Jul 20, 2026 | Company News, Compliance, Lab Management |
Labcorp will pay $14.5 million to settle DOJ allegations it billed Medicare for medically unnecessary urine drug tests by submitting claims for both presumptive and definitive testing on the same sample between 2018 and 2023.
Read More